Genmab A/S

Common Name
Genmab
Country
Denmark
Sector
Healthcare
Industry
Biotechnology
Employees
2,638
Ticker
GMAB
Exchange
NASDAQ COPENHAGEN A/S
Description
Genmab A/S is a biotechnology company that specializes in the development, manufacture, and commercialization of antibody therapies for the treatment of cancer. Founded in 1999 and headquartered in Co...

Genmab's Climate Target Data Preview

As of 2024, Genmab has disclosed 2 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 2 absolute reduction targets, signaling the company’s commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into Genmab ’s climate strategy, ambition level, and alignment with global decarbonization goals.

Target TypeScope of TargetUnitTargetTarget Year
Absolute-based Target
Scope 1 - Total, Scope 2 - Total
Metric Tonnes of CO2 equivalent (mtCO2e)
Copy restricted. Please purchase to unlock this data.
2030
Absolute-based Target
Scope 1 - Total, Scope 2 - Total
Metric Tonnes of CO2 equivalent (mtCO2e)
Copy restricted. Please purchase to unlock this data.
2050

This table provides a simplified preview of selected climate targets data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.

Insights into Genmab's Greenhouse Gas Emissions Pathways

As of 2024, Genmab has set greenhouse gas (GHG) emissions reduction targets that cover its operational emissions (Scope 1 and 2), but not its value chain emissions (Scope 3). This means its reduction efforts currently focus on direct and purchased energy emissions.

Does Genmab have a target to reduce the emissions from its operations?

As of 2024, Genmab has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources.

Genmab's most ambitious operational target is to reduce these emissions by 90% by 2050, compared to a baseline of 1,697 Metric Tonnes of CO2 equivalent (mtCO2e) in 2024.

Genmab's Operational (Scope 1+2) Emissions Pathway

20242030205004509001.35 k1.8 kBaselineTarget 2030 (-42%)Target 2050 (-90%)
Want Full Access to Genmab's Climate Targets Dataset?
Sign Up